2020•Pharmacological ResearchRequires access

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

Qing-Yun Chong, Ze-Hui Kok, Ngoc-Linh-Chi Bui, Xiaoqiang Xiang, Andrea Li‐Ann Wong, Wei Peng Yong, Gautam Sethi, Peter E. Lobie, Lingzhi Wang, Boon-Cher Goh

Open publisher page 109 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 109 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Palbociclib, Cyclin-dependent kinase, CDK inhibitor, Cyclin-dependent kinase 4, Kinase, Breast cancer, Medicine, Cancer

Back to paper search Browse research topics Original source

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib — Research Paper | ScholarLens